-
Synthetic lethality: who will share the share of the PARP inhibitor market in the future?
Time of Update: 2021-07-14
Parylenes The evolution history of PARP inhibitors Using the principle of synthetic lethality and using DNA repair inhibitors and/or cell cycle checkpoint inhibitors, single-stranded DNA damage repair and double-stranded DNA damage repair are inhibited at the same time, causing tumor cells to lose their ability to repair DNA damage, leading to tumor cells Damage repair defects and death, this is a promising targeted therapy for cancer treatment .
-
Ascent Pharmaceutical's MDM2-p53 inhibitor APG-115 enhances T cell-mediated anti-tumor immunity research results published
Time of Update: 2021-07-14
A research and development company in the clinical stage dedicated to the development of innovative drugs in the treatment of tumors, hepatitis B and aging-related diseases - Ascent Pharmaceuticals announced that the company's preclinical research results of the new drug MDM2-p53 inhibitor APG-115 are now available today The internationally renowned journal "Nature Immunology" (Nature Immunology) published, revealing the role of murine double minute homologous gene 2 (MDM2) in CD8+ T cell-mediated immunity .
-
Pfizer/Myovant Releases Phase III Clinical Results of Relugolix Combination Therapy
Time of Update: 2021-07-13
On March 25, Pfizer and Myovant announced the positive results of the LIBERT Phase III clinical trial of relugolix combined treatment of female uterine fibroids .
-
ED drugs can prolong life and prevent heart disease?
Time of Update: 2021-07-13
After comparing alprostadil with various PDE5 inhibitors, the study found that if men take PDE5 inhibitors for ED while treating stable coronary artery disease, they can not only reduce the risk of new heart attacks, but also It can also extend life expectancy .
-
Daiichi Sankyo and Sanofi terminate cooperation on 2 combination vaccines
Time of Update: 2021-07-12
Daiichi Sankyo stated that the company will stop distributing and supplying Squarekids products from March 31 .
" In addition, the two companies also decided The development cooperation of the VB-0105 combination vaccine to prevent diphtheria, Haemophilus infection, whooping cough, polio and tetanus was terminated .
-
Deqi Pharmaceutical ATG-019 is approved for Phase I clinical trial
Time of Update: 2021-07-11
Deqi Pharmaceuticals has launched a phase I clinical trial (TEACH) of ATG-019 for the treatment of advanced solid tumors and non-Hodgkin's lymphoma in Taiwan, China .
-
Genxi Bio announced the completion of the first patient enrollment in the Phase I/II registered clinical study of donor-derived allogeneic CAR-T cell therapy GC007g for relapsed/refractory B-ALL
Time of Update: 2021-07-11
The phase I/II registered clinical study of the donor-derived allogeneic, anti-CD19 chimeric antigen receptor (CAR)-T cell therapy GC007g for cell leukemia (B-ALL) completed the first patient enrollment .
-
Series Reports on Early Screening of Multiple Cancers in Benchmark Medical Care-Colorectal Cancer
Time of Update: 2021-07-11
In addition, in order to further explore the clinical application of these DNA methylation markers in the early detection of CRC, 577 plasma samples were collected (169 healthy controls, 44 non-advanced adenomas [NAA], 76 AA and 288 Example CRC) for NGS sequencing analysis .
-
Nanomaterial delivery system for mRNA vaccine
Time of Update: 2021-07-11
For example, the use of lipid nanoparticle carrier systems in animal models can increase the expression efficiency of mRNA by 1000 times compared with naked mRNA .
-
Weisheng Pharmaceutical's TransCon Human Growth Hormone Phase III clinical trial in China completed the enrollment goal on schedule
Time of Update: 2021-07-11
(RhGH) Phase III registered clinical trial on the efficacy, safety and tolerability of children with prepubertal growth hormone deficiency (GHD)", successfully completed the enrollment goal of 150 cases .
-
Kinase inhibitor?
Time of Update: 2021-07-11
Gleevec, the first protein kinase inhibitor on the market Since the description of the phosphorylation of protein substrates by the adenosine triphosphate (ATP) enzyme in 1954, human genome sequencing has revealed that approximately 538 protein kinases are responsible for signal transduction and turn on and off the growth of cancer cells .
-
Brazil Announces Final Research Results of Coxing's New Coronary Vaccine Phase III Clinical Trial
Time of Update: 2021-07-10
The protective effect of all new crown cases in China has been revised from 50.
7%, and the protective effect of new crown cases with obvious symptoms and requiring medical treatment has been revised from 78% in January to 83.
-
The first phase III clinical trial of a new treatment for cognitive impairment in schizophrenia approved in China
Time of Update: 2021-07-10
Recently, Boehringer Ingelheim's central nervous pipeline drug BI425809 for the treatment of cognitive impairment in patients with schizophrenia (CIAS) phase III clinical trial was approved by the Drug Evaluation Center of the National Medical Products Administration.
-
Nuocheng Jianhua Obutinib was approved by the National Food and Drug Administration to carry out Phase II clinical studies for the treatment of multiple sclerosis
Time of Update: 2021-07-10
Nuocheng Jianhua announced today that the company's Bruton's tyrosine kinase (BTK) inhibitor abutinib for the treatment of multiple sclerosis (MS) has passed the China National Medical Products Administration (NMPA) clinical research new drug (IND) review and approved to conduct Phase II clinical studies in China .
-
Kangtai Bio-New Coronary Inactivated Vaccine Data: Neutralizing Antibody Is 2.65 Times Recovered
Time of Update: 2021-07-10
The clinical data of the new crown vaccine compiled by the medical team of Dongxing Securities shows that the antibody titer vaccine group/recovered multiple of them ranks first in China and fourth in the world .
-
Play games to treat ADHD digital therapy cutting-edge to obtain 160 million US dollars in financing
Time of Update: 2021-07-06
Throughout the game, Akili's platform uses internal algorithms to continuously adapt to the player's needs and abilities, so as to provide a completely individualized treatment for each patient .
-
Zejing Pharmaceuticals JAK Inhibitor starts Phase 3 clinical trial for severe alopecia areata
Time of Update: 2021-07-06
On June 2, the China Drug Clinical Trial Registration and Information Disclosure Platform showed that Zejing Pharmaceuticals launched a Phase 3 clinical trial of Jacketinib Hydrochloride Tablets for the treatment of severe alopecia areata .
-
Results of the first phase III first-line immunotherapy for gastric cancer in the Chinese subgroup announced
Time of Update: 2021-07-05
● Compared with chemotherapy alone, Odivo (Navuliumab) combined with chemotherapy for the treatment of previously untreated Chinese advanced patients has achieved clinically significant overall survi
-
425 million US dollars "soaked"!
Time of Update: 2021-07-03
In November 2020, Merck invested $425 million in early cash to obtain OncoImmune and its COVID-19 inpatient treatment candidate CD24Fc (called MK-7710), which is in the phase III clinical research phase .
-
Chuangsheng Group announced the completion of a new phase of clinical trials of TST001 combined with oxaliplatin and capecitabine
Time of Update: 2021-07-02
2) Monoclonal antibody, combined with oxaliplatin and capecitabine, was administered to the first patient in a phase I clinical study of first-line locally advanced unresectable or metastatic gastric cancer .
